Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. J of Skin. 2018;2(S1):S16. doi:10.25251/skin.2.supp.16